Figure 1
From: Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells
Inhibition of cancer cell growth by ATO and DCA. (A) Combined effect of ATO (5 or 15 μM) and DCA (5 mM) on breast cancer cell growth as measured by neutral red viability assay after 3 days of treatment. BT-20, T-47D, MDA-MB-468 and MCF-10AT1 cells were treated with 5 μM ATO. MDA-MB-231, MAT and MCF-10A cells were treated with 15 μM ATO. (B) Dose response of T-47D cells towards DCA (t = 72 hours). (C) Dose response of T-47D cells towards ATO and ATO/DCA (5 mM) treatment (t = 72 hours). (D) T-47D proliferation measured as mean CFSE intensity after treatment with 5 μM ATO and/or 5 mM DCA (t = 72 hours) (higher CFSE intensity indicating less proliferation). (E) Cell death (AV+/PI+) population expressed as percentage of total cell number after 48 hours of treatment with 20 μM ATO and/or 5 mM DCA. * P ≤ 0.05, ** P ≤ 0.001, *** P ≤ 0.0001, NS - not significant (treated vs untreated). ## P ≤ 0.001, ### P ≤ 0.0001 (ATO/DCA vs ATO).